
NNK FMT
PERMANOVA p = 0.004
Post−tumor Control
Post−tumor NNK
NNK Donor
PCoA1 (71.83%)
PCoA2 (11.61%)
−0.4
−0.2
0.0
0.2
0.4
0.6
0.8
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6


NNK FMT
PERMANOVA p = 0.004
Post−tumor Control
NNK Donor
Post−tumor NNK
PCoA3 (5.29%)
PCoA1 (71.83%)
0.6
0.4
0.2
0.0
−0.2
−0.4
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6
0.8


NNK FMT
PERMANOVA p = 0.004
Post−tumor NNK
NNK Donor
Post−tumor Control
PCoA4 (2.78%)
PCoA1 (71.83%)
0.6
0.4
0.2
0.0
−0.2
−0.4
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6
0.8


NNK FMT
PERMANOVA p = 0.004
Post−tumor Control
NNK Donor
Post−tumor NNK
PCoA5 (2.56%)
PCoA1 (71.83%)
0.5
0.0
−0.5
−0.5
0.0
0.5
1.0


NNK FMT
PERMANOVA p = 0.004
Post+tumor Control
NNK Donor
Post−tumor NNK
PCoA3 (5.29%)
PCoA2 (11.61%)
0.6
0.4
0.2
0.0
−0.2
−0.4
−0.6
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6


NNK FMT
PERMANOVA p = 0.004
Post−tumor NNK
NNK Donor
Post−tumor Control
PCoA4 (2.78%)
PCoA2 (11.61%)
0.6
0.4
0.2
0.0
−0.2
−0.4
−0.6
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6


NNK FMT
PERMANOVA p = 0.004
NNK Donor
Post−tumor Control
Post−tumor NNK
PCoA5 (2.56%)
PCoA2 (11.61%)
0.5
0.0
−0.5
−0.5
0.0
0.5


NNK FMT
PERMANOVA p = 0.004
Post−tumor NNK
NNK Donor
Post−tumor Control
PCoA4 (2.78%)
PCoA3 (5.29%)
−0.6
−0.4
−0.2
0.0
0.2
0.4
0.6


NNK FMT
PERMANOVA p = 0.004
NNK Donor
Post−tumor Control
Post−tumor NNK
PCoA5 (2.56%)
PCoA3 (5.29%)
0.5
0.0
−0.5
−0.5
0.0
0.5


NNK FMT
PERMANOVA p = 0.004
NNK Donor
Post−tumor Control
Post−tumor NNK
PCoA5 (2.56%)
PCoA4 (2.78%)
0.5
0.0
−0.5
−0.5
0.0
0.5